Selected article for: "additional file and MERS cov"
Author: Arabi, Yaseen M.; Asiri, Ayed Y.; Assiri, Abdullah M.; Aziz Jokhdar, Hani A.; Alothman, Adel; Balkhy, Hanan H.; AlJohani, Sameera; Al Harbi, Shmeylan; Kojan, Suleiman; Al Jeraisy, Majed; Deeb, Ahmad M.; Memish, Ziad A.; Ghazal, Sameeh; Al Faraj, Sarah; Al-Hameed, Fahad; AlSaedi, Asim; Mandourah, Yasser; Al Mekhlafi, Ghaleb A.; Sherbeeni, Nisreen Murad; Elzein, Fatehi Elnour; Almotairi, Abdullah; Al Bshabshe, Ali; Kharaba, Ayman; Jose, Jesna; Al Harthy, Abdulrahman; Al Sulaiman, Mohammed; Mady, Ahmed; Fowler, Robert A.; Hayden, Frederick G.; Al-Dawood, Abdulaziz; Abdelzaher, Mohamed; Bajhmom, Wail; Hussein, Mohamed A.
Title: Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-ß1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial
  • Document date: 2020_1_3
    • ID: 0cah15lg_64
    Snippet: Additional file 1: Table S1 . Baseline characteristics of intention-to-treat (ITT) population. Table S2 . Summary of interventions and cointerventions. Table S3 . Primary outcome: 90-day mortality. Table S4 . Secondary outcomes. Table S5 . Subgroup analyses. Table S6 . Classification of adverse events in the MIRACLE trial (MERS-CoV Infection tReated with A Combination of Lopinavir/ritonavir and intErferon-β1b) using the NIH Common Terminology Cr.....
    Document: Additional file 1: Table S1 . Baseline characteristics of intention-to-treat (ITT) population. Table S2 . Summary of interventions and cointerventions. Table S3 . Primary outcome: 90-day mortality. Table S4 . Secondary outcomes. Table S5 . Subgroup analyses. Table S6 . Classification of adverse events in the MIRACLE trial (MERS-CoV Infection tReated with A Combination of Lopinavir/ritonavir and intErferon-β1b) using the NIH Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. Table S7 . Summary of adverse events by severity. Table S8 . Summary of protocol violations.

    Search related documents:
    Co phrase search for related documents
    • additional file and MERS cov: 1, 2, 3, 4, 5, 6, 7
    • additional file and MERS cov infection: 1, 2, 3
    • additional file and mortality primary outcome: 1, 2, 3
    • additional file and primary outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • additional file and protocol violation: 1
    • additional file and secondary outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • additional file and subgroup analysis: 1
    • adverse event and CTCAE adverse event: 1, 2
    • adverse event and MERS cov: 1, 2
    • adverse event and MERS cov infection: 1
    • adverse event and mortality primary outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • adverse event and primary outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adverse event and secondary outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • adverse event and severity adverse event: 1, 2, 3, 4, 5, 6
    • adverse event and subgroup analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • baseline characteristic and mortality primary outcome: 1
    • baseline characteristic and primary outcome: 1, 2
    • CTCAE adverse event and severity adverse event: 1
    • ITT population and subgroup analysis: 1